Last reviewed · How we verify
NCT04806607
19Gauge Fine Needle Biopsy (FNB) Versus 22Gauge FNB for Endoscopic Ultrasound Guided Liver Biopsy (EUS-LB)
NA trial testing 19G FNB in Chronic Liver Disease in 42 participants. Completed in 16 March 2022.
16 March 2022
Quick facts
| Lead sponsor | Geisinger Clinic |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 42 |
| Start date | 30 April 2021 |
| Primary completion | 16 March 2022 |
| Estimated completion | 16 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 19G FNB
- 22G FNB
Conditions studied
- Chronic Liver Disease — all drugs for Chronic Liver Disease →
Sponsor
Geisinger Clinic
Who can join
Adults 18 to 89, any sex, with Chronic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the adequacy of EUS-LB using a 19G core needle compared to a 22G core needle in a prospective randomized study.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Comparing a 19-gauge fine-needle biopsy needle with a 22-gauge fine-needle biopsy needle for EUS-guided liver biopsy sampling: a prospective randomized study.
Diehl DL, Sangwan V, Johal AS, Khara HS, et al · · 2024 · cited 12× · PMID 38141686 · DOI 10.1016/j.gie.2023.12.022
Verify or expand the search:
- PubMed search for NCT04806607
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Liver Disease
Currently open trials in the same condition.
- NCT06592820 — Endoscopic Ultrasound Shear Wave Elastography Study · recruiting
- NCT06318949 — Albumin Modifications as Early Biomarkers of Chronic Liver Diseases · NA · recruiting
- NCT06743464 — Effect of Perioperative Oral Rifaximin on Early Graft Dysfunction in Adult Living Donor Liver Transplant · NA · recruiting
- NCT06587568 — Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases · NA · active not recruiting
- NCT06493799 — In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Pl · Phase 3 · recruiting
Other Geisinger Clinic trials
Trials by the same sponsor.
- NCT07197801 — Evaluation of a Peer Recovery Support Program Adapted to Target Retention in Clinic-based Medication for Opioid Use Diso · NA · recruiting
- NCT06936709 — Perioperative Colchicine for TKA · Phase 4 · not yet recruiting
- NCT07042477 — Integrated Telemedicine Program Evaluation · NA · recruiting
- NCT07028398 — CMSL Ambulatory Sensitive Condition Nudge Study 2 · NA · recruiting
- NCT06696066 — PEERS Pilot: Peer Recovery Support Program to Support Engagement in Medication for Opioid Use Disorder · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04806607 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Geisinger Clinic
- Last refreshed: 20 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806607.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing